LUPIN LABORATORIES LTD
Article Abstract:
Lupin Laboratories Ltd (LLL) posted a net profit of Rs152.20 million for the six months ended December 1997. LLL has a 42 percent market share in the domestic market for the anti-TB drug, Ethambutol. Its group companies include Lupin Chemicals and Lupin Agrochemicals. Its major brands include R-Cinex, R-Cin, Ceff, AKT- 4 and Combutol. It plans to focus on cephalosporins. The company has enlarged its product portfolio to include antibiotics. (rk) ------------------------------------------------------------ Performance of Lupin Laboratories Ltd (Rs in million) ------------------------------------------------------------ Particulars Year ended 6 months ended June 1997 December 1997 ------------------------------------------------------------ Sales 6,424.40 3,183.30 ------------------------------------------------------------ Gross profit 796.40 439.00 ------------------------------------------------------------ Net profit 242.70 152.20 ------------------------------------------------------------ Equity 242.30 242.30 ------------------------------------------------------------ Earnings per share (Rs) 10.00 12.60 ------------------------------------------------------------ Market price of share (Rs) 142.80 142.80 ------------------------------------------------------------
Comment:
Has a 42% market share in the domestic market for the anti-tuberculosis drug, Ethambutol
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
CIPLA
Article Abstract:
The net profit of the pharmaceutical firm, Cipla increased by 11.3 percent to Rs402.50 million in the first half of 1997-98. Sales increased by 8 percent. Cipla has set up plants at five locations in Maharashtra. It has set up an in-house research & development centre which specialises in process reengineering. Its formulations include Norflox, Ciplox, Novamox, Asthalin, Novaclox and Asthalin Inhaler. It is likely to post a sales growth of 20 percent per annum in the next few years. (rk) ------------------------------------------------------------ Financial Performance of Cipla (Rs in million) ------------------------------------------------------------ Particulars 1996-97 1H 1997-98 ------------------------------------------------------------ Sales 4,520.00 2,680.50 ------------------------------------------------------------ Gross profit 1,198.60 598.50 ------------------------------------------------------------ Net profit 705.60 402.50 ------------------------------------------------------------ Equity 199.90 199.90 ------------------------------------------------------------ Earnings per share (Rs) 35.30 40.30 ------------------------------------------------------------ Market price of share (Rs) 846.00 846.00 ------------------------------------------------------------
Comment:
Indian pharmaceutical firm is likely to post a sales growth of 20% per annum in the next few years
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
TURBULENT TIMES
Article Abstract:
The Indian pharmaceutical industry is witnessing change and consolidation. India has signed Trade-Related Intellectual Property Rights (TRIPS). The Government of India will adopt product patents in 2005 AD. Life saving drugs will be available at reasonable prices. In the next ten years, around 60 pharmaceutical products will be removed from patent protection. The bulk drug industry has been affected by reduction in import duties, over capacity, competition and dumping from China. The prices of bulk drugs have increased due to excise duty hike from 10 percent to 18 percent. (rk)
Comment:
India: Pharmaceutical industry is witnessing change & consolidation as country signs Trade-Related Intellectual Property Rights
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: PRIYADARSHINI CEMENT LIMITED KESORAM INDUSTRIES LIMITED CHETTINAD CEMENT'S PAT FALLS 47%
- Abstracts: SAVINGS AND INVESTMENT GLOOMY BUT CREDIBLE. GIC MULLS NON-LIFE SAVINGS POLICY
- Abstracts: ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED SHASUN CHEMICALS NET AT Rs5-Cr
- Abstracts: HCL INFOSYSTEMS LTD HP-TCS JV TO MAKE SME ACCOUNTING PACKAGES. THE SAD EFFECT UNSETTLES PC PRICING
- Abstracts: IPCA LABORATORIES LIMITED ON A STRONG COMEBACK TRAIL - PARKE DAVIS INDIA LTD. JB CHEMICALS DECLARES 1:1 BONUS